Provided by Tiger Trade Technology Pte. Ltd.

Astellas Pharma, Inc.

15.74
+0.24001.55%
Volume:71.47K
Turnover:1.12M
Market Cap:28.18B
PE:211.70
High:16.19
Open:15.16
Low:15.16
Close:15.50
52wk High:16.19
52wk Low:8.37
Shares:1.79B
Float Shares:1.75B
Volume Ratio:0.33
T/O Rate:0.00%
Dividend:0.51
Dividend Rate:3.26%
EPS(TTM):0.0744
EPS(LYR):0.0628
ROE:7.95%
ROA:6.68%
PB:2.75
PE(LYR):250.47

Loading ...

Company Profile

Company Name:
Astellas Pharma, Inc.
Exchange:
PINK LIMITED
Establishment Date:
1923
Employees:
13643
Office Location:
2-5-1, Nihonbashi-Honcho,Chuo,Tokyo,Japan
Zip Code:
103-8411
Fax:
- -
Introduction:
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.